1233 related articles for article (PubMed ID: 25877962)
1. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.
Spring MD; Lin JT; Manning JE; Vanachayangkul P; Somethy S; Bun R; Se Y; Chann S; Ittiverakul M; Sia-ngam P; Kuntawunginn W; Arsanok M; Buathong N; Chaorattanakawee S; Gosi P; Ta-aksorn W; Chanarat N; Sundrakes S; Kong N; Heng TK; Nou S; Teja-isavadharm P; Pichyangkul S; Phann ST; Balasubramanian S; Juliano JJ; Meshnick SR; Chour CM; Prom S; Lanteri CA; Lon C; Saunders DL
Lancet Infect Dis; 2015 Jun; 15(6):683-91. PubMed ID: 25877962
[TBL] [Abstract][Full Text] [Related]
2. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.
van der Pluijm RW; Imwong M; Chau NH; Hoa NT; Thuy-Nhien NT; Thanh NV; Jittamala P; Hanboonkunupakarn B; Chutasmit K; Saelow C; Runjarern R; Kaewmok W; Tripura R; Peto TJ; Yok S; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Lek D; Huy R; Dhorda M; Chotivanich K; Ashley EA; Mukaka M; Waithira N; Cheah PY; Maude RJ; Amato R; Pearson RD; Gonçalves S; Jacob CG; Hamilton WL; Fairhurst RM; Tarning J; Winterberg M; Kwiatkowski DP; Pukrittayakamee S; Hien TT; Day NP; Miotto O; White NJ; Dondorp AM
Lancet Infect Dis; 2019 Sep; 19(9):952-961. PubMed ID: 31345710
[TBL] [Abstract][Full Text] [Related]
3. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.
Amaratunga C; Lim P; Suon S; Sreng S; Mao S; Sopha C; Sam B; Dek D; Try V; Amato R; Blessborn D; Song L; Tullo GS; Fay MP; Anderson JM; Tarning J; Fairhurst RM
Lancet Infect Dis; 2016 Mar; 16(3):357-65. PubMed ID: 26774243
[TBL] [Abstract][Full Text] [Related]
4. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
van der Pluijm RW; Tripura R; Hoglund RM; Pyae Phyo A; Lek D; Ul Islam A; Anvikar AR; Satpathi P; Satpathi S; Behera PK; Tripura A; Baidya S; Onyamboko M; Chau NH; Sovann Y; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Chutasmit K; Saelow C; Runcharern R; Kaewmok W; Hoa NT; Thanh NV; Hanboonkunupakarn B; Callery JJ; Mohanty AK; Heaton J; Thant M; Gantait K; Ghosh T; Amato R; Pearson RD; Jacob CG; Gonçalves S; Mukaka M; Waithira N; Woodrow CJ; Grobusch MP; van Vugt M; Fairhurst RM; Cheah PY; Peto TJ; von Seidlein L; Dhorda M; Maude RJ; Winterberg M; Thuy-Nhien NT; Kwiatkowski DP; Imwong M; Jittamala P; Lin K; Hlaing TM; Chotivanich K; Huy R; Fanello C; Ashley E; Mayxay M; Newton PN; Hien TT; Valecha N; Smithuis F; Pukrittayakamee S; Faiz A; Miotto O; Tarning J; Day NPJ; White NJ; Dondorp AM;
Lancet; 2020 Apr; 395(10233):1345-1360. PubMed ID: 32171078
[TBL] [Abstract][Full Text] [Related]
5. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study.
Amato R; Lim P; Miotto O; Amaratunga C; Dek D; Pearson RD; Almagro-Garcia J; Neal AT; Sreng S; Suon S; Drury E; Jyothi D; Stalker J; Kwiatkowski DP; Fairhurst RM
Lancet Infect Dis; 2017 Feb; 17(2):164-173. PubMed ID: 27818095
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial.
Lon C; Manning JE; Vanachayangkul P; So M; Sea D; Se Y; Gosi P; Lanteri C; Chaorattanakawee S; Sriwichai S; Chann S; Kuntawunginn W; Buathong N; Nou S; Walsh DS; Tyner SD; Juliano JJ; Lin J; Spring M; Bethell D; Kaewkungwal J; Tang D; Chuor CM; Satharath P; Saunders D
PLoS One; 2014; 9(3):e93138. PubMed ID: 24667662
[TBL] [Abstract][Full Text] [Related]
7. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam.
Thanh NV; Thuy-Nhien N; Tuyen NT; Tong NT; Nha-Ca NT; Dong LT; Quang HH; Farrar J; Thwaites G; White NJ; Wolbers M; Hien TT
Malar J; 2017 Jan; 16(1):27. PubMed ID: 28086775
[TBL] [Abstract][Full Text] [Related]
8. Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment.
Leang R; Taylor WR; Bouth DM; Song L; Tarning J; Char MC; Kim S; Witkowski B; Duru V; Domergue A; Khim N; Ringwald P; Menard D
Antimicrob Agents Chemother; 2015 Aug; 59(8):4719-26. PubMed ID: 26014949
[TBL] [Abstract][Full Text] [Related]
9. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations.
Duru V; Khim N; Leang R; Kim S; Domergue A; Kloeung N; Ke S; Chy S; Eam R; Khean C; Loch K; Ken M; Lek D; Beghain J; Ariey F; Guerin PJ; Huy R; Mercereau-Puijalon O; Witkowski B; Menard D
BMC Med; 2015 Dec; 13():305. PubMed ID: 26695060
[TBL] [Abstract][Full Text] [Related]
10. Assessing the asymptomatic reservoir and dihydroartemisinin-piperaquine effectiveness in a low transmission setting threatened by artemisinin resistant Plasmodium falciparum.
Falq G; Van Den Bergh R; De Smet M; Etienne W; Nguon C; Rekol H; Imwong M; Dondorp A; Kindermans JM
Malar J; 2016 Sep; 15(1):446. PubMed ID: 27585957
[TBL] [Abstract][Full Text] [Related]
11. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
[TBL] [Abstract][Full Text] [Related]
12. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.
Witkowski B; Duru V; Khim N; Ross LS; Saintpierre B; Beghain J; Chy S; Kim S; Ke S; Kloeung N; Eam R; Khean C; Ken M; Loch K; Bouillon A; Domergue A; Ma L; Bouchier C; Leang R; Huy R; Nuel G; Barale JC; Legrand E; Ringwald P; Fidock DA; Mercereau-Puijalon O; Ariey F; Ménard D
Lancet Infect Dis; 2017 Feb; 17(2):174-183. PubMed ID: 27818097
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Smithuis F; Kyaw MK; Phe O; Win T; Aung PP; Oo AP; Naing AL; Nyo MY; Myint NZ; Imwong M; Ashley E; Lee SJ; White NJ
Lancet Infect Dis; 2010 Oct; 10(10):673-81. PubMed ID: 20832366
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.
Leang R; Barrette A; Bouth DM; Menard D; Abdur R; Duong S; Ringwald P
Antimicrob Agents Chemother; 2013 Feb; 57(2):818-26. PubMed ID: 23208711
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.
Phong NC; Chavchich M; Quang HH; San NN; Birrell GW; Chuang I; Martin NJ; Manh ND; Edstein MD
Malar J; 2019 Jan; 18(1):10. PubMed ID: 30654808
[TBL] [Abstract][Full Text] [Related]
16. Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent
Stone W; Mahamar A; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Youssouf A; Diallo M; Soumare HM; Kaur H; Lanke K; Ter Heine R; Bradley J; Issiaka D; Diawara H; Traore SF; Bousema T; Drakeley C; Dicko A
Lancet Microbe; 2022 Jan; 3(1):e41-e51. PubMed ID: 35028628
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison.
Smithuis F; Kyaw MK; Phe O; Aye KZ; Htet L; Barends M; Lindegardh N; Singtoroj T; Ashley E; Lwin S; Stepniewska K; White NJ
Lancet; 2006 Jun; 367(9528):2075-85. PubMed ID: 16798391
[TBL] [Abstract][Full Text] [Related]
18. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.
Tran TH; Dolecek C; Pham PM; Nguyen TD; Nguyen TT; Le HT; Dong TH; Tran TT; Stepniewska K; White NJ; Farrar J
Lancet; 2004 Jan; 363(9402):18-22. PubMed ID: 14723988
[TBL] [Abstract][Full Text] [Related]
19. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M; van der Pluijm RW; Weya J; Njuguna P; Ngama M; Kalume P; Mwambingu G; Ngetsa C; Wambua J; Boga M; Mturi N; Lal AA; Khuroo A; Taylor WRJ; Gonçalves S; Miotto O; Dhorda M; Mutinda B; Mukaka M; Waithira N; Hoglund RM; Imwong M; Tarning J; Day NPJ; White NJ; Bejon P; Dondorp AM
Lancet Infect Dis; 2021 Oct; 21(10):1395-1406. PubMed ID: 34111412
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam.
Rovira-Vallbona E; Van Hong N; Kattenberg JH; Huan RM; Hien NTT; Ngoc NTH; Guetens P; Hieu NL; Mai TT; Duong NTT; Duong TT; Phuc BQ; Xa NX; Erhart A; Rosanas-Urgell A
J Antimicrob Chemother; 2020 Aug; 75(8):2272-2281. PubMed ID: 32437557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
